Compare Merck & Co., Inc. (MRK) vs NetFlix Inc (NFLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs NetFlix Inc — how do they compare? Merck & Co., Inc. trades at $146.1 (market cap $351.28B), while NetFlix Inc trades at $70.49 (market cap $298.01B). The key difference: Merck & Co., Inc. is the larger of the two by market cap, and Merck & Co., Inc. pays a 2.39% dividend while NetFlix Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and NetFlix Inc for 125 Days on average.
| MRK | NFLX | |
|---|---|---|
Market Cap | $351.28B | $298.01B |
Volume | 7,969,665 | 45,805,108 |
Sector | Health | Media |
52-Week High | $156.43 | $124.13 |
52-Week Low | $82.49 | $67.06 |
Typical Hold Time | 98 Days | 125 Days |
Enterprise Value | $398.04B | $303.19B |
Dividend Yield | 2.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $144.96, up 1.52% today, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 72.97% gross margin and 28.07% net income margin for 2025, though its P/E ratio of 113.9 indicates high valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid competitive pressures.
The outlook is mixed: analyst consensus is bullish with a $158.78 price target, but technical indicators and a high P/E suggest near-term caution. Key risks include integration challenges from acquisitions and macroeconomic headwinds affecting pharmaceutical R&D investment. Revenue growth and pipeline execution remain critical for sustained upside.
Netflix trades at $69.70, up 1.47% today, with strong fundamentals including 28.2% net margin and 49.5% ROE. The stock shows bearish technical signals despite beating earnings expectations for three consecutive quarters. Recent news highlights Netflix's live sports strategy and content investments, while analyst consensus remains bullish with a $89.78 price target representing 29% upside potential.
Netflix presents a compelling growth story with expanding profitability and strategic content investments, though technical weakness and competitive pressures warrant caution. The company's strong cash flow generation and institutional interest support long-term upside, but investors should monitor execution risks in the evolving streaming landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About NetFlix Inc
Netflix Inc. is an Internet subscription service for watching television shows and movies. Subscribers can instantly watch unlimited television shows and movies streamed over the Internet to their televisions, computers, and mobile devices and in the United States, subscribers can receive standard definition DVDs and Blu-ray Discs delivered to their homes.
Read more on NFLX →
